Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa

Core Viewpoint - Arcutis Biotherapeutics has terminated its promotion agreement with Kowa Pharmaceuticals for ZORYVE, and will take over the sales and promotion responsibilities in the pediatric and primary care markets [1][2][3] Group 1: Agreement Termination - The promotion agreement with Kowa Pharmaceuticals was mutually terminated on January 23, 2026, which involved the sales and promotion of ZORYVE to primary care physicians and pediatricians in the U.S. [1] - Under the termination agreement, Kowa will cease all sales and promotions of ZORYVE, and Arcutis will not be required to make any further payments [3] Group 2: Future Plans - Arcutis plans to assume responsibility for the sales and promotion of ZORYVE in pediatric and primary care settings, with further updates expected during the Q4 earnings call on February 25, 2026 [2] - The company is also expanding its dermatology salesforce to enhance ZORYVE prescriptions in dermatology practices [2] Group 3: Product Information - ZORYVE cream is indicated for the treatment of mild to moderate atopic dermatitis in pediatric patients aged 2 to 5 years and in patients aged 6 years and older [4] - ZORYVE foam is indicated for the treatment of plaque psoriasis and seborrheic dermatitis in patients aged 12 years and older and 9 years and older, respectively [5] Group 4: Safety Information - ZORYVE is contraindicated in patients with moderate to severe liver impairment and has flammability warnings due to its propellant [6] - Common adverse reactions for ZORYVE cream and foam include upper respiratory tract infection, diarrhea, headache, and nausea, with varying percentages across different age groups and formulations [7][8][9][10] Group 5: Company Overview - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases, with a growing portfolio of advanced targeted topicals [11]